Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
RD-1302 by Nanjing Bioheng Biotech for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
RD-1302 is under clinical development by Nanjing Bioheng Biotech and currently in Phase I for Relapsed Acute Myeloid Leukemia. According...
RD-1302 by Nanjing Bioheng Biotech for Refractory Acute Myeloid Leukemia: Likelihood of Approval
RD-1302 is under clinical development by Nanjing Bioheng Biotech and currently in Phase I for Refractory Acute Myeloid Leukemia. According...
RD-1301 by Nanjing Bioheng Biotech for Non-Hodgkin Lymphoma: Likelihood of Approval
RD-1301 is under clinical development by Nanjing Bioheng Biotech and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData,...
RD-1301 by Nanjing Bioheng Biotech for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
RD-1301 is under clinical development by Nanjing Bioheng Biotech and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute...
CTA-101 by Nanjing Bioheng Biotech for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
CTA-101 is under clinical development by Nanjing Bioheng Biotech and currently in Phase I for Diffuse Large B-Cell Lymphoma. According...